Gastroenterology

Gastroenterology

Volume 128, Issue 3, March 2005, Pages 789-792
Gastroenterology

Editorials
Therapies for hepatitis B: Where to from here?

https://doi.org/10.1053/j.gastro.2005.01.017Get rights and content

Section snippets

Introducing RNA silencing

RNA silencing or posttranscriptional gene (PTG) silencing, is the process whereby double-stranded RNA (dsRNA) induces the sequence-specific degradation of homologous messenger RNA (mRNA). The current model of RNAi involves a multi-step process.3, 4 First, the initial dsRNA (>26bp) is cleaved by an RNAse III-like enzyme, termed Dicer, to generate 21–23nt fragments of siRNA. Second, an ATP-dependent RNA helicase recognizes these short duplexes and resolves the siRNA duplex into 2 single-stranded

RNAi-mediated inhibition of viral replication

In plants, PTG silencing and RNAi play critical roles in genome surveillance, protecting the cell from inappropriate expression of repetitive sequences and transposable elements, as well as a major antiviral defense mechanism.8 The ability to tap into this innate antiviral pathway to devise possible treatments against viruses is rapidly emerging as a new field of therapeutic intervention. To date, RNAi has been used effectively to inhibit the replication of several different pathogenic human

Delivery

A major impediment to using RNAi technology for therapeutic benefit has been the development of efficient delivery systems for siRNAs. However, several companies are developing clinically appropriate approaches to overcome this obstacle (see Nucleonics Inc. at www.nucleonicsinc.com). Previous methods relied on harsh lipid-based transfection reagents to introduce siRNAs into cells in culture and are either inefficient and/or unsuitable for use in animals. Interestingly, injected siRNAs have been

Resistance

The selection of resistant strains of poliovirus10 and HIV29 in cultures treated with specific siRNAs is a reminder that a single nucleotide mutation is all that is needed to allow the virus to escape the effect of a single specific siRNA. Emergence of siRNA resistance is a major concern that will need to be addressed, particularly for viruses encoding error-prone polymerases such as those of HIV-1 and HBV. In the study of Wu et al,2 sequence analysis of an HBV clinical isolate showed that a

Conclusions and future challenges

It is striking how rapidly the field has moved from an initial discovery phase to a stage where implementation and evaluation of siRNA technology in a therapeutic setting is expected sometime this year. However, our understanding of the biological mechanisms underlying RNAi lags behind the momentum to apply this technology to human diseases such as cancer and infectious diseases caused by HIV-1, HCV, and HBV. Clearly the objective, in the short term, is to improve viral delivery systems with

References (29)

  • A. Fire et al.

    Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

    Nature

    (1998)
  • G.R. Stark et al.

    How cells respond to interferons?

    Annu Rev Biochem

    (1998)
  • S.M. Elbashir et al.

    Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

    Nature

    (2001)
  • G.A. Coburn et al.

    siRNAsa new wave of RNA-based therapeutics

    J Antimicrob Chemother

    (2003)
  • Cited by (0)

    View full text